Advertisement
Posters CLINICAL TRIALS & OUTCOME MEASURES| Volume 21, SUPPLEMENT 2, S101-S102, October 2022

174 Identification of physiological characteristics at baseline and 1 and 6 months that segregate lung function response to ivacaftor using proteomic analysis

DOI:https://doi.org/10.1016/S1569-1993(22)00864-5
174 Identification of physiological characteristics at baseline and 1 and 6 months that segregate lung function response to ivacaftor using proteomic analysis
Previous Article173 Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study
Next Article175 QuestionCF 2022: Updating the top 10 research priorities for clinical research in cystic fibrosis
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(22)00864-5

      Copyright

      © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX